Why Sarepta Therapeutics (SRPT) Stock Is Down Today

Sarepta Therapeutics (SRPT) shares plummeted 44.4% after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy, Elevidys, prompting a temporary halt to shipments for non-ambulatory patients and a pause in a related clinical trial. The market reaction reflects concerns that the event could increase regulatory scrutiny and slow adoption of Elevidys, which accounted for over 50% of Sarepta's Q4 2024 sales. Year to date, Sarepta is down 84.1% and trades 88% below its 52-week high.

Analysis

Sarepta Therapeutics (SRPT) experienced a severe 44.4% decline in its share price following the announcement of a second patient death linked to its Duchenne muscular dystrophy gene therapy, Elevidys. This event prompted the company to temporarily halt shipments of Elevidys for non-ambulatory patients and pause an associated clinical trial, signaling significant operational and clinical disruptions. The market's sharp negative reaction, underscored by a previous 24.9% stock drop three months prior due to a similar patient death, reflects escalating concerns over the therapy's safety profile, potential for increased regulatory scrutiny, physician hesitancy, and consequently, a slowdown in Elevidys adoption. This is particularly critical as Elevidys accounted for over 50% of Sarepta's sales in Q4 2024, making it a cornerstone of the company's revenue and growth strategy. The stock's volatility is further highlighted by 25 moves greater than 5% over the last year, with the current price of $19.70 reflecting an 84.1% year-to-date decline and an 88% drop from its 52-week high of $163.85. The prior fatal event involved acute liver failure, a known risk for AAV-mediated gene therapies, which Sarepta had attributed partially to a CMV infection while maintaining a favorable benefit-risk profile for Elevidys at that time.

Key Decisions for Investors

• Investors should recognize the heightened risk profile for Sarepta Therapeutics, as the second patient death linked to Elevidys significantly jeopardizes the future revenue stream from this key product and invites intensified regulatory oversight.
• It is crucial to monitor Sarepta's updates regarding the investigation into the patient death, communications with regulatory agencies like the FDA, and any revisions to Elevidys's prescribing information or clinical trial protocols, as these will directly impact the therapy's viability.
• Given the precipitous stock decline and the central role of Elevidys in Sarepta's valuation, a thorough reassessment of investment theses is warranted, factoring in the increased probability of materially adverse outcomes for the gene therapy program and the company's financial outlook.